VistaGen Therapeutics (VTGN) AI Stock Analysis

• Market Cap: $99.71M
• Dividend Yield: N/A
• Average Volume (3M): 511.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: -33.00%
• EPS Growth: 54.91%
• Country: US
• Employees: 48
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.47
• Shares Outstanding: 30,680,471
• 10 Day Avg. Volume: 336,098
• 30 Day Avg. Volume: 511,289
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.03
• Enterprise Value/Revenue: 4.70
• Enterprise Value/Gross Profit: 6.37
• Enterprise Value/Ebitda: -0.05
• 1Y Price Target: $14.33
• Price Target Upside: 392.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 61 Neutral
• Price Target: $3.50 ▲(20.27% Upside)

VistaGen Therapeutics shows potential with strong technical momentum and promising clinical advancements. However, financial performance remains a significant concern due to ongoing losses and negative cash flow. The company's valuation is impacted by its development stage, reflected in a negative P/E ratio. The earnings call provided positive guidance on clinical progress, but operational challenges persist. Corporate events, while positive, are not weighted in the final score.

Positive Factors

Clinical Program Advancements

The advancement of fasedienol in late Phase III trials for social anxiety disorder indicates potential for regulatory approval, addressing a significant unmet need and enhancing market position.

Strategic Leadership Appointment

The appointment of an experienced Chief Corporate Development Officer enhances strategic planning and partnership cultivation, crucial for growth and commercialization efforts.

Strong Financial Position

A robust cash position supports ongoing clinical trials and strategic initiatives, providing financial stability and flexibility for future development.

Negative Factors

Consistent Net Losses

Ongoing net losses highlight the challenge of achieving profitability, which is crucial for long-term sustainability and investor confidence.

Increased R&D Expenses

Rising R&D costs reflect significant investment in pipeline development but also pressure financial resources, impacting short-term cash flow.

Negative Cash Flow

Negative cash flow underscores the need for improved cash management and operational efficiency to ensure long-term financial health.

VistaGen Therapeutics Business Overview & Revenue Model

Company Description

VistaGen Therapeutics (VTGN) is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat central nervous system (CNS) disorders, with a primary emphasis on anxiety, depression, and other related conditions. The company utilizes its proprietary drug development platforms, including its stem cell technology, to create and advance new treatments that address significant unmet medical needs. VistaGen's core products include AV-101, an oral candidate for the treatment of major depressive disorder, and PH94B, a novel intranasal formulation for social anxiety disorder.

How the Company Makes Money

VistaGen Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company may receive funding through various sources, including government grants, partnerships with pharmaceutical companies, and potential milestone payments tied to the progress of its drug candidates in clinical trials. Additionally, VistaGen may generate revenue through licensing agreements or collaborations that allow other companies to develop or market its products. As the company advances its drug candidates through clinical trials and approaches regulatory approval, potential sales from these products could become significant revenue streams.

VistaGen Therapeutics Financial Statement Overview

Summary

VistaGen Therapeutics faces significant challenges with consistent losses and negative cash flow. However, a strong equity position and manageable debt levels provide some stability. While the revenue growth shows potential, the company must focus on improving operational efficiency and profitability to ensure long-term success.

Income Statement

The company's revenue growth has been volatile, with a significant drop this year compared to the previous year. Gross profit margin remains stable due to the low cost structure, but the net profit margin is severely negative. The EBIT and EBITDA margins are also deeply negative, indicating operational inefficiency. Despite these challenges, there is a slight increase in revenue compared to the previous year, showing potential for future growth.

Balance Sheet

VistaGen Therapeutics has a relatively low debt-to-equity ratio, indicating a conservative capital structure. However, the return on equity is negative, impacted by consistent net losses. The equity ratio is strong, suggesting financial stability and a solid foundation for future growth. Despite these strengths, the company needs to improve profitability to leverage its equity effectively.

Cash Flow

The company's free cash flow is negative but shows improvement from the previous year, suggesting progress towards better cash management. Operating cash flow remains negative, but the ratio to net income indicates that cash losses are less severe than income losses. Continued focus on reducing cash burn is crucial for future financial health.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	646.00K	486.00K	1.06M	-227.00K	1.11M	1.09M
Gross Profit	477.00K	486.00K	1.06M	-227.00K	1.11M	1.09M
EBITDA	-58.28M	-55.34M	-32.45M	-58.74M	-47.05M	-17.44M
Net Income	-55.78M	-51.42M	-29.36M	-59.25M	-47.76M	-17.93M
Balance Sheet
Total Assets	68.92M	84.34M	123.65M	21.09M	74.64M	108.28M
Cash, Cash Equivalents and Short-Term Investments	63.18M	80.48M	119.17M	16.64M	68.14M	103.11M
Total Debt	2.36M	1.51M	2.12M	2.72M	3.04M	3.72M
Total Liabilities	12.16M	13.95M	9.37M	9.01M	9.93M	16.30M
Stockholders Equity	56.77M	70.39M	114.29M	12.08M	64.72M	91.98M
Cash Flow
Free Cash Flow	-50.12M	-42.29M	-25.87M	-49.93M	-45.46M	-12.35M
Operating Cash Flow	-50.07M	-42.10M	-25.81M	-49.72M	-45.26M	-12.07M
Investing Cash Flow	-8.47M	-13.15M	-61.00K	-740.30K	-200.40K	-275.40K
Financing Cash Flow	4.61M	3.21M	128.40M	-1.04M	10.48M	114.10M

VistaGen Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.91
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTGN, the sentiment is Neutral. The current price of 2.91 is below the 20-day moving average (MA) of 3.31, below the 50-day MA of 3.01, and above the 200-day MA of 2.66, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 39.33 is Neutral, neither overbought nor oversold. The STOCH value of 5.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VTGN.

VistaGen Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VTGN	61 Neutral	$99.71M	―	-46.28%	―	-33.00%	54.91%
SAVA	43 Neutral	100.48M	-0.81	0.00%	―	0.00%	-553.86%
CLSD	42 Neutral	18.89M	-0.66	88.41%	―	-44.63%	26.79%
VTVT	38 Underperform	67.18M	-6.74	0.00%	―	-98.30%	54.90%
JSPR	35 Underperform	37.87M	-0.39	0.00%	―	0.00%	-17.96%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

VistaGen Therapeutics Corporate Events

VistaGen Reports Q1 2026 Financial Results and Update

On August 7, 2025, Vistagen reported its fiscal year 2026 first-quarter financial results and provided a corporate update. The company highlighted the progress of its lead program, fasedienol, for treating social anxiety disorder, with key trial results expected in late 2025 and early 2026. Vistagen is optimistic about the potential impact of fasedienol, as there is currently no FDA-approved acute treatment for social anxiety disorder. The company is also advancing other intranasal pherine product candidates for major depressive disorder and women’s health conditions. Financially, Vistagen reported increased R&D expenses due to its ongoing trials and a net loss of $15.1 million for the quarter ended June 30, 2025.

Vistagen Appoints Elissa Cote as Chief Development Officer

On June 25, 2025, Vistagen Therapeutics announced the appointment of Elissa Cote as Chief Corporate Development Officer, effective June 23, 2025. Ms. Cote, with nearly 30 years of experience in biopharmaceuticals, will lead strategic opportunities to advance Vistagen’s pherine platform and cultivate partnerships. Her appointment is seen as pivotal for Vistagen’s growth, as she brings expertise in business development and strategic transactions, which are crucial for the company’s future commercial launches and partnerships.

VistaGen Files Prospectus to Raise $175 Million

On June 17, 2025, Vistagen announced a prospectus supplement filed with the SEC to offer and sell shares of its common stock, aiming to raise up to $175 million. The company also reported its fiscal year 2025 financial results, highlighting significant progress in its clinical-stage pipeline, including the PALISADE program for fasedienol in social anxiety disorder. Vistagen’s ongoing trials and development efforts, such as the PALISADE-3 and PALISADE-4 trials, aim to address unmet needs in mental health and women’s health, with potential implications for future FDA submissions and market positioning.